Bosh sahifaTWST • NASDAQ
add
Twist Bioscience Corp
39,24 $
Seans yopilganidan keyin:(0,00%)0,00
39,24 $
Yopilgan:2-may, 16:01:57 (GMT-4) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
37,71 $
Kunlik diapazon
38,45 $ - 40,45 $
Yillik diapazon
33,16 $ - 60,90 $
Bozor kapitalizatsiyasi
2,34 mlrd USD
Oʻrtacha hajm
1,19 mln
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 88,71 mln | 24,08% |
Joriy xarajat | 77,48 mln | 2,03% |
Sof foyda | -31,59 mln | 26,54% |
Sof foyda marjasi | -35,61 | 40,80% |
Har bir ulushga tushum | -0,53 | 29,33% |
EBITDA | -28,26 mln | 27,17% |
Amaldagi soliq stavkasi | -0,31% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 270,83 mln | -12,96% |
Jami aktivlari | 608,58 mln | -16,95% |
Jami passivlari | 152,64 mln | 6,91% |
Umumiy kapital | 455,94 mln | — |
Tarqatilgan aksiyalar | 59,65 mln | — |
Narxi/balansdagi bahosi | 4,93 | — |
Aktivlardan daromad | — | — |
Kapitaldan daromad | -15,80% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -31,59 mln | 26,54% |
Operatsiyalardan naqd pul | -21,43 mln | 6,73% |
Sarmoyadan naqd pul | -1,54 mln | -136,88% |
Moliyadan naqd pul | 17,94 mln | 1 318,19% |
Naqd pulning sof oʻzgarishi | -5,07 mln | 74,84% |
Boʻsh pul | -11,25 mln | -3,00% |
Haqida
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
The company was represented by Leproust at a March 2021 tabletop exercise at the Munich Security Conference simulating an outbreak of weaponized monkeypox.
In May 2021, Twist Bioscience and Genome Project-Write launched a new CAD platform for whole genome design. The CAD will automate workflows to enable collaborative efforts critical for scale-up from designing plasmids to megabases across entire genomes. Wikipedia
Tashkil etilgan
2013
Xodimlar soni
923
